• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Contract Manufacturing: Trials & Tribulations of Today’s Supply Chains

    Analytical Testing in Nutraceuticals: Methods and Mindsets to Uphold Quality

    Nutrition and Flavor: Formulating for Modern Product Preferences

    What Do Consumers Know About the Gut Microbiome?

    How Will the European Green Deal Impact Dietary Supplements?
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    PLT to Supply Traceable, Standardized Organic Elderberry Extract

    Herbalist and Alchemist Celebrates 40th Anniversary, Announces Expansion

    BASF Venture Capital and Aqua-Spark invest in Sea6 Energy

    Lauren Aronson Joins Amin Talati Wasserman, LLP

    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    PLT to Supply Traceable, Standardized Organic Elderberry Extract

    Herbalist and Alchemist Celebrates 40th Anniversary, Announces Expansion

    BASF Venture Capital and Aqua-Spark invest in Sea6 Energy

    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome

    Vitamin D May Prevent Changes to Liver Enzymes and Lipid Profile After Exhaustive Exercise
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    PLT to Supply Traceable, Standardized Organic Elderberry Extract

    Herbalist and Alchemist Celebrates 40th Anniversary, Announces Expansion

    BASF Venture Capital and Aqua-Spark invest in Sea6 Energy

    Lauren Aronson Joins Amin Talati Wasserman, LLP

    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    PLT to Supply Traceable, Standardized Organic Elderberry Extract

    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome

    Vitamin D May Prevent Changes to Liver Enzymes and Lipid Profile After Exhaustive Exercise

    Omega-3 Fatty Acids Linked to Reduced Episodes of Depression

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Atlantia Clinical Trials

    Bioenergy Life Science, Inc. (BLS)

    Aiya America, Inc. (Aiya Matcha)

    Botanic Healthcare LLC

    Sabinsa Corporation
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Atlantia Clinical Trials

    Bioenergy Life Science, Inc. (BLS)

    Aiya America, Inc. (Aiya Matcha)

    Botanic Healthcare LLC

    Sabinsa Corporation
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Dual Tracking of New Ingredients as Dietary Supplements and Drugs

    It’s possible to develop novel ingredients for both the dietary supplement and drug markets, but timing is important and there are gray areas.

    Dual Tracking of New Ingredients as Dietary Supplements and Drugs
    By Todd Harrison, Venable04.08.21
    An issue that is rarely addressed during the ingredient development stage is whether to move forward as a dietary ingredient or as a drug ingredient. The two paths, however, do not need to be mutually exclusive if ingredient development is done correctly. Specifically, an ingredient may be used in both drugs and dietary supplements where the ingredient was first marketed as a dietary ingredient.1

    Alternatively, an ingredient which was not first marketed as a dietary supplement may still be used as or in a dietary supplement if the ingredient has not undergone “substantial clinical investigation.” However, FDA has not defined this phrase. Thus, while there is little doubt that Phase III clinical trials would preclude its use, there is strong argument that Phase I and limited Phase II clinical trials would not necessarily preclude an ingredient being studied under an IND from being marketed as a dietary supplement in the future.

    Regardless, determining if an ingredient may be marketed as both a drug and also a dietary supplement depends on if the ingredient was studied as a drug first and if it was marketed as dietary supplement before the initiation of “substantial clinical investigation.” From a developmental standpoint, it is best to market the product as a dietary ingredient prior to obtaining an IND and the institution of substantial clinical trials.

    Drugs vs Supplements: By the Book
    More specifically, under the Federal Food, Drug, and Cosmetic Act (FDCA), drugs are defined as products intended for use in the diagnosis, treatment, or prevention of disease,2 and are subject to extensive premarket approval requirements.3 These requirements focus on the unique formulation of a drug and its active ingredient to evaluate the drug’s safety and efficacy. 

    By comparison, dietary supplements are considered a subset of food4 that are ingested and intended to support or maintain health via one or more “dietary ingredients.”5 While dietary supplements are normally not subject to premarket approval requirements like drugs, the FDCA provides that a product cannot be marketed as a dietary supplement if it includes an “article” that has been: 1) authorized for investigation as a new drug; 2) for which substantial clinical investigations have been instituted on the article and their existence made public; and 3) was not marketed as a food or dietary supplement prior to being authorized for investigation as a new drug.6 The key question that needs to be asked is whether the ingredient was first marketed as a food or dietary supplement before the filing of the IND and initiation of “substantial clinical investigation” have been made public.

    On the first part of the question, the statute is relatively straightforward in establishing that an ingredient can properly be considered a dietary ingredient for use as or in a dietary supplement so long as the ingredient was first marketed as a food or dietary supplement before becoming the subject of a drug investigation. The second part of the question, while seemingly self-explanatory, involves several important nuances.

    First, the FDA has not specifically defined “substantial clinical trials” in the context of dietary ingredients both under the FDCA and its associated regulations. The legislative history behind the Dietary Supplement Health and Education Act (DSHEA) is equally thin, merely noting that “substantial clinical investigations” do not include a special type of IND referred to as “compassionate use” or single-patient studies7 and the FDA has never formally or informally attempted to define the limits of this provision.

    ‘Substantial’ Distinction
    The only insight available is in 2008 when the FDA requested comments to § 331(ll) which is the exclusionary language related to food ingredients that had undergone substantial clinical trials.8 Specifically, the FDA requested comments related to “substantial clinical investigations” that have been instituted as well as its applicability to dietary ingredients as a subgroup of foods.9 FDA, however, has never discussed the comments received nor attempted to define the term “substantial clinical investigations,” or attempted to argue that § 331(ll) applies to dietary supplements. 

    Moreover, there is an important distinction between the exclusion language for food and food ingredients under § 331(ll) and its sister provision for dietary supplements under § 321(ff). Under § 321(ff), “substantial clinical investigation” is directly tied to an “authorized” investigation for a new drug. This means that ingredients that are first used under an authorized IND and undergo substantial clinical trials cannot be used as or in a dietary supplement. By comparison, § 331(ll) does not feature the IND component found in § 321(ff). Instead, the statute as worded only encompasses the institution of “substantial clinical investigations,” which could be interpreted to mean any phase of a clinical trial. 

    As discussed, while the FDCA features “substantial clinical evaluation” within its exclusion provisions for both foods and dietary supplements, there is no formal definition of “substantial clinical evaluation” found in either context, both under the FDCA and its relevant regulations. 

    Despite the lack of specific definitions in either context, we note that the agency’s recent actions against dietary supplement products suggest that “substantial” likely refers to clinical evaluation past Phase I trials, and to an extent limited Phase II trials. For example, the FDA has issued warning letters relying on the exclusion language,10 but did so against products that were ultimately approved under a new drug application or that had recently begun Phase III clinical trials.11

    Thus, a product (or ingredient) that has only undergone a Phase I trial, was part of an abandoned Phase I trial, or only completed a limited Phase II trial is unlikely to be considered the subject of “substantial clinical trials.” The same outcome would result (at least in the dietary supplement context) if the IND itself is withdrawn before the trials are completed, given that the exclusion language for dietary ingredients requires that an authorized IND be in effect in addition to “substantial clinical evaluation.”12

    Interpreting FDA Action & Warnings
    Regardless, the FDA’s reluctance to impose its own definition of “substantial clinical investigations” provides a window into its thought process, as it has only raised the issue a few times in warning letters (e.g., vinpocetine, CBD) when it believes Phase II and III trials have been conducted. Accordingly, there is a strong argument that limited Phase I and Phase IIA trials are unlikely to be considered substantial if the drug pathway was abandoned shortly thereafter and was unrelated to the safety of the ingredient.

    Indeed, an important nuance here is that the clinical trials were abandoned and did not continue. If the trials proceeded to Phase III or possibly Phase IIA, FDA would take the position that the initiation of substantial clinical investigations relates back to the initiation of Phase I clinical trials for sure and likely to the filing of the IND. Thus, if the Phase I clinical trial started in April 2016 and the dietary ingredient was launched in 2017, and Phase III clinical trials started in January 2018, FDA will likely take the position that April 2016 is the date of preclusion or the date the IND was approved.

    In the end, it is possible to develop a new or novel ingredient for both the dietary supplement and drug market. However, timing is the key and it is best to introduce the ingredient as a dietary supplement prior to the IND and before the institution of Phase I clinical trials to unequivocally avoid the preclusion issue. 

    References & Resources
    1. While FDA has not defined the term “marketed” under the Federal Food, Drug and Cosmetic Act or its implementing regulations, the agency takes this term to generally mean commercially available and held for sale in the U.S. See, e.g., FDA, FDA 101: Dietary Supplements, https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements (last updated July 15, 2015) (noting that FDA oversight of dietary supplements generally begins where the product “enters the marketplace.”). 
    2. 21 U.S.C. § 321(g)(1).
    3. See, e.g., 21 U.S.C. § 355 et seq.
    4. 21 U.S.C. § 321(ff).
    5. Id. § 321(ff)(1).
    6. Id. § 321(ff)(3)(B)(ii). For purposes of this exclusion, FDA has interpreted “authorized for investigation as a new drug” to mean that an investigational new drug application (“IND”) has been submitted and taken effect. See FDA, Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues (Oct. 2016), https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-new-dietary-ingredient-notifications-and-related-issues.
    7. Dietary Supplement Health & Education Act, Pub. L. No. 103-417, 108 Stat. 4325 (1994).
    8. 73 Fed. Reg. 43937, 43939 (July 29, 2008).
    9. Id
    10. See, e.g., FDA Warning Letter to The Dragontree Apothecary LLC (Apr. 28, 2020) (noting the exclusion as applied to a CBD product); FDA Warning Letter to X2Zero (Dec. 8, 2016) (noting the same as applied to a sibutramine product); FDA Warning Letter to Life Enhancement Products, Inc. (Nov. 22, 2002) (noting the same as applied to a galantamine product).
    11. See, e.g., Request for Comment on the Status of Vinpocetine, 81 Fed. Reg. 61700 (Sept. 7, 2016) (noting Phase III clinical trials).
    12. 21 U.S.C. § 321(ff).


    About the Author: Todd Harrison is partner with Venable, which is located in Washington, D.C. He advises food and drug companies on a variety of FDA and FTC matters, with an emphasis on dietary supplement, functional food, biotech, legislative, adulteration, labeling and advertising issues. He can be reached at 575 7th St. NW, Washington, D.C. 20004, Tel: 202-344-4724; E-mail: taharrison@venable.com.
    Related Searches
    • Dietary Supplements
    • Regulations
    Related Knowledge Center
    • Dietary Supplements
    • Regulations
    Loading, Please Wait..
    Trending
    • Study Examines Vitamin K2 Content In Cheese
    • Evolution Nutraceuticals To Discontinue Challenged Claims For ‘Cardio Miracle’ Dietary Supplement
    • Vitamin K2 Status May Impact Blood Pressure And Pulse Wave Velocity
    • Chenland Nutritionals Self-Affirms GRAS For Cumin UP60 Ingredient
    • Omega-3 Fatty Acids Linked To Reduced Episodes Of Depression
    Breaking News
    • PLT to Supply Traceable, Standardized Organic Elderberry Extract
    • Herbalist and Alchemist Celebrates 40th Anniversary, Announces Expansion
    • BASF Venture Capital and Aqua-Spark invest in Sea6 Energy
    • Lauren Aronson Joins Amin Talati Wasserman, LLP
    • Vitamin K2 May Ameliorate Polycystic Ovary Syndrome
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • A Growing Herbal Products Market Still Faces Formidable Threats, Challenges
    • Analytical Testing in Nutraceuticals: Methods and Mindsets to Uphold Quality
    • Nutrition and Flavor: Formulating for Modern Product Preferences
    • Contract Manufacturing: Trials & Tribulations of Today’s Supply Chains
    • How Will the European Green Deal Impact Dietary Supplements?
    • What Do Consumers Know About the Gut Microbiome?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    PLT to Supply Traceable, Standardized Organic Elderberry Extract
    Herbalist and Alchemist Celebrates 40th Anniversary, Announces Expansion
    BASF Venture Capital and Aqua-Spark invest in Sea6 Energy
    Coatings World

    Latest Breaking News From Coatings World

    PPG Appoints Brad Budde Vice President and Chief Digital Officer
    AkzoNobel Creates Bespoke Colors for Volotea’s 10th Anniversary Livery
    Axalta: Red Continues as Most Preferred Car Color of Consumers in Mexico
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Study: RhinAer Treatment Improves Chronic Rhinitis Symptoms
    CE Mark Granted for IVF Decision Support Tool
    FDA Approves Full-Body MRI Compatibility With Inspire Therapy
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Octapharma Adopts Automated Application System from Schreiner MediPharm
    Rentschler Biopharma Appoints Mark Caswell as VP, Site Head
    Cellipont Unveils Plans for Cell Therapy Facility in Houston
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Estée Lauder Companies Delivers Strong Results in Fiscal 2022
    Fastest-Growing Consumer Product Companies in the U.S.
    Winky Lux is Among the Top 20 Fastest-Growing Beauty Companies
    Happi

    Latest Breaking News From Happi

    Fenty Beauty Introduces Eaze Drop’lit All-Over Glow Enhancer Makeup
    EPA Calls for Nominations for 2023 Green Chemistry Challenge Awards
    Strands Hair Care Introduces The Hair Lab
    Ink World

    Latest Breaking News From Ink World

    Flint Group to Highlight AQUACode Inks, Xiekon IDERA at Corrugated Week 2022
    DuPont Selects 2022 Lavoisier and Pedersen Award Medalists
    Chemours Begins Commissioning Newest Sand Mine in Clay County, FL
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Techkon USA announces latest handheld spectrodensitometer
    Maxcess China now manufacturing solid dies in Huzhou
    Avery Dennison debuts new adhesive for wine and spirits
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    INDA Appoints Director of Membership and Industry Relations
    Nexwear Acquires Incontinence Products Brand Lily Bird
    Because Market Expands into Retail Stores
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Clears Accelus' Toro-L Interbody Fusion System
    FDA OKs VySpine's VyPlate Anterior Cervical Plates
    Moximed Raises $40M for Knee OA Shock Absorber Implant
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    ORNL Celebrates Launch of Frontier, the World’s Fastest Supercomputer
    DuPont Names 2022 Lavoisier and Pedersen Award Medalists
    Photonic Glasses Give Solar Panels Pleasing Colors

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login